Janssen Research & Development LLC has identified new partnerships through the company’s Janssen Human Microbiome Institute (JHMI), a program that develops microbial products through innovation and discovery.
"These collaborations and investments will create critical new insights to address metabolic disorders through microbiome-based diagnostics and therapeutics," Dirk Gevers, global head of JHMI, said in a statement. "By partnering with entrepreneurs, biotechs and academics and bringing innovative opportunities together with our expertise, we look to move microbiome science forward and deliver future solutions that promote individual health."
JHMI, in conjunction with Janssen Disease Interception Accelerator (DIA), is joining with DayTwo Ltd. and the Weizmann Institute of Science in Rehovot, Israel, to research microbiome-based health solutions for metabolic disorders. JHMI is also working with Bioqube Ventures as part of Caelus Health, a portfolio company of Johnson & Johnson Innovation -- JJDC Inc.
"We are excited about the collaborations with DayTwo and the Weizmann Institute of Science, and the JJDC investment in Caelus as they bring us one step closer to harnessing the potential of microbiome science," Anuk Das, JHMI's head of scientific innovation, said. "DayTwo's advanced prediction engine algorithm, the Weizmann Institute of Science's robust research capabilities and Caelus's portfolio of microbiota-based products provide unique opportunities to learn more about the role that the microbiome plays in disease and health."
Alerts Sign-up